(±SE) of 380±90 μg per sample (10 puffs) of formaldehyde was detected as formaldehydereleasing agents. Extrapolating from the results at high voltage, an e-cigarette user vaping at a rate of 3 ml per day would inhale 14.4±3.3 mg of formaldehyde per day in formaldehyde-releasing agents. This estimate is conservative because we did not collect all of the aerosolized liquid, nor did we collect any gas-phase formaldehyde. One estimate of the average delivery of formaldehyde from conventional cigarettes is approximately 150 μg per cigarette, 3 or 3 mg per pack of 20 cigarettes. Daily exposures of formaldehyde associated with cigarettes, e-cigarettes from the formaldehyde gas phase, and e-cigarettes from aerosol particles containing formaldehyde-releasing agents are shown in Figure 1 .
Inhaled formaldehyde has a reported slope factor of 0.021 kg of body weight per milligram of formaldehyde per day for cancer (http://oehha. ca.gov/risk/pdf/TCDBcas061809.pdf). Among persons with a body weight of 70 kg, the incremental lifetime cancer risk associated with long-term cigarette smoking at 1 pack per day may then be estimated at 9×10 −4 . If we assume that inhaling formaldehyde-releasing agents carries the same risk per unit of formaldehyde as the risk associated with inhaling gaseous formaldehyde, then long-term vaping is associated with an incremental lifetime cancer risk of 4.2×10 −3 . This risk is 5 times as high (as compared with the risk based on the calculation of Miyake and Shibamoto shown in Fig. 1 ), or even 15 times as high (as compared with the risk based on the calculation of Counts et al. shown in Fig. 1 ) as the risk associated with long-term smoking. In addition, formaldehydereleasing agents may deposit more efficiently in the respiratory tract than gaseous formaldehyde, were derived from Miyake and Shibamoto 2 and Counts et al. 3 These values were multiplied by 20 cigarettes per pack. Thus, they are an average of the values used in the protocols from the International Organization for Standardization, the Massachusetts Department of Public Health, and Health Canada. Data on the daily exposure from e-cigarettes from the formaldehyde gas phase were calculated from the data in Kosmider et al. 4 We estimated daily exposure by applying our measured e-liquid consumption rates of 0.13 mg per milliliter (at 3.3 V) and 0.18 mg per milliliter (at 5 V) of vapor produced to the measured gas-phase formaldehyde values described by Kosmider et al. 4 : 0.13 μg per 1050 ml of vapor (at 3.2 V) and 27 μg per 1050 ml vapor at (4.8 V) for mixed glycerol and propylene glycol samples. Data on the daily exposure from liquid-phase aerosol particulate matter in e-cigarettes were calculated as the value of formaldehyde (as a formaldehyde-releasing agent [FRA]) exposure per day for commercial e-liquid (Halo "café mocha" flavor, 6 mg per milliliter of nicotine), measured from 10 successive aerosolized samples analyzed at 3 concentrations each. FRAs were identified by means of nuclear magnetic resonance spectroscopy (see the Supplementary Appendix, available with the full text of this letter at NEJM.org) and quantified by relative integration against an internal standard. The two I bars on the left indicate standard deviations, and the I bar on the right indicates the standard error. Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following:
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correction A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke (January 1, 2015;372:11-20). In the stub column of Table 1 (page 15), under "Prestroke modified Rankin scale score," the final subcategory should have been >2, rather than <2. The article is correct at NEJM.org.
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